Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$587.9 million.

  • Avidity Biosciences' Cash from Investing Activities fell 2187.19% to -$587.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$309.4 million, marking a year-over-year increase of 5812.86%. This contributed to the annual value of -$854.2 million for FY2024, which is 55672.41% down from last year.
  • As of Q3 2025, Avidity Biosciences' Cash from Investing Activities stood at -$587.9 million, which was down 2187.19% from $185.5 million recorded in Q2 2025.
  • Avidity Biosciences' Cash from Investing Activities' 5-year high stood at $185.5 million during Q2 2025, with a 5-year trough of -$587.9 million in Q3 2025.
  • In the last 5 years, Avidity Biosciences' Cash from Investing Activities had a median value of -$17.6 million in 2022 and averaged -$79.1 million.
  • Data for Avidity Biosciences' Cash from Investing Activities shows a peak YoY increase of 146650.0% (in 2022) and a maximum YoY decrease of 3332380.95% (in 2022) over the last 5 years.
  • Avidity Biosciences' Cash from Investing Activities (Quarter) stood at -$84.1 million in 2021, then surged by 90.76% to -$7.8 million in 2022, then surged by 757.05% to $51.0 million in 2023, then crashed by 225.73% to -$64.2 million in 2024, then crashed by 816.17% to -$587.9 million in 2025.
  • Its Cash from Investing Activities was -$587.9 million in Q3 2025, compared to $185.5 million in Q2 2025 and $157.2 million in Q1 2025.